Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Blueprint Medicines Corp
(NQ:
BPMC
)
108.55
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
What 5 Analyst Ratings Have To Say About Blueprint Medicines
March 01, 2022
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 01, 2022
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...
Via
Benzinga
Earnings Scheduled For February 16, 2022
February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.
Via
Benzinga
EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder
January 28, 2022
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies
February 28, 2022
Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies....
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 25, 2022
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
February 17, 2022
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Analyst Ratings For Blueprint Medicines
January 25, 2022
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BP...
Via
Benzinga
Earnings Preview: Blueprint Medicines
February 15, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
January 25, 2022
Needham cut Medtronic plc (NYSE:MDT) price target f...
Via
Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
Analyst Ratings for Blueprint Medicines
June 17, 2021
Blueprint Medicines (NASDAQ:BPMC) has observed the followi...
Via
Benzinga
50 Biggest Movers From Yesterday
January 06, 2022
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...
Via
Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
January 05, 2022
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage...
Via
Benzinga
Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition
November 29, 2021
Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration...
Via
Benzinga
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
November 13, 2021
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
Via
Talk Markets
Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates
November 09, 2021
Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...
Via
Benzinga
Blueprint Medicines Corp (BPMC) Q3 2021 Earnings Call Transcript
October 28, 2021
BPMC earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
August 05, 2021
Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.
Via
The Motley Fool
Topics
Earnings
Exposures
COVID-19
Financial
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Blueprint Medicines: Q2 Earnings Insights
July 29, 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
June 20, 2021
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.